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Abstract 
Background: It remains unclear whether radial increases the risk of operator or patient radiation 
exposure when performed by expert operators 
Objectives: To determine whether radial access increases radiation exposure 
Methods: We randomly assigned 8404 patients, with or without ST-segment elevation acute 
coronary syndrome, to radial or femoral access for coronary angiography and percutaneous 
intervention, and collected fluoroscopy time and dose area product (DAP). In the radiation sub-
study (RAD-MATRIX), we anticipated that 13 or more operators, each wearing a thorax 
(primary endpoint), wrist and head (secondary endpoints) lithium fluoride thermo luminescent 
dosimeter and randomizing at least 13 patients per access site were needed to establish non-
inferiority of radial versus femoral access. 
Results: Among eighteen operators, performing 777 procedures in 767 patients, the non-
inferiority primary endpoint was not achieved (p-value for non-inferiority=0.843). Operator 
equivalent dose at the thorax was significantly higher with radial than femoral access (77 µSv 
[IQR:40-112] vs. 41 µSv [IQR:23-59], p=0.02). After normalization of operator radiation dose 
by fluoroscopy time or DAP, the difference remained significant. Radiation dose at wrist or head 
did not differ between radial and femoral access. Thorax operator dose did not differ in the right 
radial (84 µSv [IQR:47-146]) compared to the left radial access (52 µSv [IQR:33-92]; p=0.15) In 
the overall MATRIX population, fluoroscopy time (10 min; IQR:6-16 vs. 9 min IQR:5-15; 
p<0.0001] and DAP—available in 7570 procedures and 6902 patients—(65 Gy*cm2 [IQR:29-
120] vs. 59 Gy*cm
2
 [26-110]; p=0.0001) were higher with radial as compared to femoral access.
Conclusions: Radial, as compared with femoral access is associated with greater operator and
patient radiation exposure when performed by expert operators in current practice. Radial
operators and institutions should be sensitized towards radiation risks and adopt adjunctive radio-
protective measures.
Key Words: Radiation dose –Radial access –Femoral access –Acute coronary syndromes –PCI 
Abbreviations 
ACS: acute coronary syndrome 
DAP: dose area product 
MATRIX: Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic 
Implementation of angioX 
PCI: percutaneous coronary intervention 
STEMI: ST-segment elevationmyocardial infarction 
Condensed abstract 
Operator radiation exposure during percutaneous coronary procedures for acute coronary 
syndromes was evaluated in 18 operators participating in the MATRIX trial. Operator equivalent 
dose was measured after randomization for vascular access (radial vs femoral). The radial 
approach was associated with a significant higher operator radiation dose compared to femoral 
access. In term of patient exposure, fluoroscopy time and dose area product were significantly 
higher with radial as compared to femoral access. Radial operators should pay special attention 
to radio-protective measures in order to minimize the effects of radiation to patients, staff and 
themselves. 
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Introduction 
The use of radial, instead of femoral, access for coronary angiography and percutaneous 
coronary intervention (PCI) has been associated to lower risk of bleeding, vascular complications 
and greater survival in patients with acute coronary syndrome undergoing invasive 
management(1,2). European clinical practice guidelines endorse the use of radial access in 
patients with non-ST elevation acute coronary syndromes undergoing invasive management with 
a class I recommendation over femoral access, (3) and the uptake of radial access is increasing 
worldwide (4). 
However, prior studies have raised concerns over the increased risk of radiation exposure 
for both patients and operators with radial instead of femoral access (5). Only a minority of 
randomized controlled studies evaluated radiation doses (5), especially in ACS patients( 6) and 
none used dedicated dosimeters to assess operator exposure. As part of the MATRIX 
(Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic 
Implementation of angioX) programme (NCT01433627), (7) we collected fluoroscopy time and 
dose area product and equipped radial operators consenting to participate with dedicated 
dosimeters during study conduct to assess operator radiation dose with radial or femoral access. 
Methods 
Study design and population 
The design of the MATRIX trial and of the radiation (RAD-MATRIX) substudy has been 
previously reported (7,8). Briefly, all patients with an ACS with or without ST-segment elevation 
myocardial infarction were randomized to radial or femoral access (see web extra material). Only 
expert radial operators were involved in the RAD-MATRIX substudy. 
Study protocol and randomization 
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Before the coronary angiography all patients were centrally randomized (1:1) to radial or 
femoral access for diagnostic angiography and percutaneous coronary intervention if clinically 
indicated. The randomisation sequence was computer generated and modified using 
minimisation on intended new or ongoing use of ticagrelor or prasugrel, presence or absence of 
STEMI, troponin positivity and anticipated use of immediate PCI in non-STEMI patients. 
Operators participating in the radiation sub-study were to follow central randomization in regards 
to radial or femoral access for the primary endpoint comparison (operator radiation exposure at 
thorax), and for the patient radiation exposure comparison. A further randomization was 
performed in patients centrally allocated to radial access based on the patient identification (ID) 
number with odd ID numbers assigned to right radial and even ID numbers to left radial access. 
These patient IDs were automatically generated by the centralized web-based randomization and 
data capture system, so were not under control of the study personnel. This allowed a fairly 
balanced proportion of right radial access versus left radial access, used to assess whether the use 
of left radial as compared to right radial is associated to lower radiation burden (secondary 
endpoint). 
Procedures 
Access site management during and after the diagnostic or therapeutic procedure was left 
to the discretion of the treating physician and closure devices were allowed as per local practice. 
Standard operator radioprotection was ensured using a lead apron, a thyroid lead collar, lower 
body X-ray curtain fixed on the angiographic table and an upper mobile leaded glass suspended 
from the ceiling. Staged procedures were allowed, with no restriction with respect to timing, 
during which the protocol mandated that the access site remained as originally allocated. 
Radiation Measurement 
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Radiation measures collected were fluoroscopy time (expressed in minutes) and the DAP 
(expressed in Gy*cm
2
). The DAP is the product of the absorbed dose to air and the cross-
sectional area of the X-ray field for all segments of an interventional radiology procedure. This 
parameter was measured using specially designed ionization chambers mounted at the collimator 
system and calculated by the software present in each angiographic system. DAP provides a 
good estimation of the total radiation energy delivered to a patient during a procedure and is 
correlated with the long-term stochastic risk of cancer (9). 
The operator radiation exposure was measured for each participating operator with three 
dedicated lithium fluoride thermo-luminescent dosimeters with a range of linearity from 1 µGy 
to 10 Gy, separate for femoral, left radial and right radial randomized access site. They were to 
be worn during each procedure by the participating operator on the left wrist, at mid thorax level, 
in the breast pocket outside the lead apron and at head level (in the middle front to measure the 
eye dose) (Fig S1- S2). The dosimeters used different detectors according to their location 
(superficial for the wrist, 3 mm depth for the eye and 10 mm depth for the thorax). Each 
dosimeter was distributed to operators in a sealed envelope and was labelled with operator’s 
code, access site (femoral, right or left radial) and body destination (eye, thorax or wrist – 3 
locations time 3 access sites equals 9 dosimeters per operator). No protocol violation was 
declared by participating operators regarding type and position of dosimeters throughout study 
execution. All dosimeters were collected for central reading at TECNORAD co. (Verona, Italy) 
and represent cumulative exposure during all procedures performed by the operator, separate for 
femoral, left radial, and right radial randomized access site. After central reading and correction 
for the radiation weighting factor (for X rays this factor is 1) the results were expressed as 
Equivalent doses in microSievert. The Equivalent dose at thorax was also converted in operator 
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effective dose dividing it by a factor 33 according with an apron thickness 0.5 mm lead 
equivalent with a tube voltage under the table (10). Patient effective dose has been calculated 
using a conversion factor of 0.20 mSv/Gy*cm
2
, as previously shown (11).
Statistical analysis 
The primary non-inferiority hypothesis was that radial access was not associated to higher 
operator radiation dose as compared to femoral access(8).Since dosimeters measure the 
cumulative procedural radiation dose for each operator, the sample size was calculated for the 
number of operators (i.e. dosimeters) needed rather than for the number of procedures or 
patients. Using previous information(12), it was estimated that at least 13 operator dosimeters 
were needed in order to prove non-inferiority with anabsolute non-inferiority margin of 25 µSv, 
one-sided alpha level of 0.05 and 80%power. An arbitrary minimum of 13 procedures per 
operator and per main access site was mandated to minimize the risks of imbalances due to 
variation in the complexity of the diagnostic or therapeutic procedures within each operator. The 
non-inferiority test for the primary outcome was performed using a one-sided unpaired t-test to 
estimate the upper bound of the confidence interval of the difference in thorax radiation dosage 
comparing radial versus femoral on the operator level. Differently, superiority testing for the 
primary end-pointwas performed using two-sided Wilcoxon rank-sum unpaired test. A further 
secondary analysis using a paired Wilcoxon rank-sum test was also performed. Details on the 
statistical analysis are available in the web extra material. 
Endpoints 
The primary end-point of the study was the cumulative operator radiation dose at the 
thorax. Secondary end-points included operator radiation dose at left wrist or at head level, 
patient procedural radiation dose assessed with DAP values as well as total fluoroscopy time. 
Published in final edited form as: J Am Coll Cardiol. 2017 May 23;69(20):2530-2537. doi: 10.1016/j.jacc.2017.03.018
8 
Role of the funding source 
The MATRIX program was designed by the last author and approved by the institutional 
review board at each participating center. The RAD MATRIX substudy(8) was pre-specified in 
the main study protocol and approved by all participating centers as amended number 5 to the 
original study protocol. MATRIX was sponsored by the Italian Society of Invasive Cardiology 
(GISE), a nonprofit organization, and received grant support from The Medicines Company and 
TERUMO (see Online Appendix). The sponsor and funders had no role in study design, data 
collection, data monitoring, analysis, interpretation, or writing of the report. Sponsor and 
companies had no role in study design, data collection, data monitoring, analysis, interpretation, 
or writing of the report. AS, MR, DH and MV had unrestricted access to all the data of the trial. 
AS and MV had final responsibility for the decision to submit for publication. 
Results 
Between October 2011 and November 2014, 8404 patients in 78 centers in Italy, the 
Netherlands, Spain, and Sweden were randomly allocated to radial (4197 patients) or femoral 
access (4207 patients). DAP was collected for 6902 patients and a total of 7570 procedures 
(Online Figure 3). A total of 767 patients undergoing 777 procedures were included in the 
operator radiation sub-study (RAD MATRIX) performed by 18 operators (Online Figure 3). 
Four operators refused to further randomize radial patients to left or right radial access (due to 
the unwillingness to sustain a prolonged uncomfortable position during left radial access in three 
operators, and in one due to perceived lack of clinical equipoise between left and right radial 
access) and were excluded from this sub-analysis. As a result, 252 radial procedures were 
performed in 250 patients by 14 operators, which were allocated to left radial (131 procedures in 
130 patients) or right radial access site (121 procedures in 120 patients) (Online Figure 3) 
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Procedural Characteristics 
Clinical characteristics between radial and femoral groups were similar (Online Table 1). 
Percutaneous coronary intervention was attempted in more than 80% of the patients in each 
group (Table 1). Patients allocated to the radial group more frequently received the non-
randomly allocated access than patients in the femoral group (7% vs. 5%: p=0.0002). In the RAD 
MATRIX subsample, cross over rates were balanced in the two access groups (Table 1). 
Patient Radiation Exposure 
Median fluoroscopy time was higher in the radial (10.2 min; IQR: 6-16) compared to 
femoral group (9.1 min; IQR: 5.1-15, p<0.0001, Table 1). Median DAP values were also higher 
in the radial (64.7 Gy*cm
2
; IQR: 28.6-120.3) compared to the femoral group (59.1 Gy*cm
2
;IQR: 25.9-109.5, p=0.0001, Table 1). Mean difference of DAP values between radial and 
femoral access stratified for pre-specified subgroups is shown in Online Figure 4. The results 
were consistent according to the angiographic system employed (Online Table 3). Fluoroscopy 
time and DAP values were consistently correlated in the radial (R=0.56) as well as in the femoral 
group (R=0.56) (Online Figure 5). 
Operator Radiation Exposure 
Radial or Femoral Access 
The primary non-inferiority hypothesis was not reached (mean difference 34.34 µSv with 
an upper 95% confidence limit of 49.57); p-value for non-inferiority= 0.843); median operator 
dose per procedure at the thorax level was higher in the radial compared to femoral access group 
(77 µSv; IQR: 39.9-112 vs. 41 µSv IQR: 23.4-58.5, respectively, p-value for superiority= 0.019, 
Central Illustration and Table 2). A paired analysis yielded identical results. After 
normalization of the operator dose either for fluoroscopy times or DAP, the difference between 
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radial and femoral access remained significant (Table 2). Procedural operator doses at left wrist 
and head levels did not differ, although both were numerically higher with radial access (Central 
Illustration and Table 2). The higher radiation dose with radial as compared to femoral access 
was consistent across individual operators (Online Figure 5). 
Left or Right Radial Access 
The baseline and procedural features, including DAP and fluoroscopy time, were similar 
between left and right radial access groups (Online Table 2). Median procedural operator dose at 
the thorax did not differ in the right radial (84 µSv) compared to the left radial access (52 µSv; 
p=0.15; Table 3 and Figure 1). Compared to femoral access, radiation dose did not differ 
compared to the left radial access, whereas was significantly higher in the right radial access 
(Online Tables 4 and 5). The radiation doses at wrist and head did not differ in the right radial 
compared to the left radial access group (Table 3 and Figure 1). 
Discussion 
Our study is to date the largest study evaluating the radiation exposure in patients and 
operators during percutaneous coronary interventions with radial or femoral access. Our main 
finding is that in the setting of ACS with or without ST-segment elevation, operator and patient 
radiation exposure is higher with radial compared to femoral access. The average increase in 
radiation exposure for patients undergoing radial instead of femoral access was relatively small, 
in the range of 10%. However, the radial, compared to femoral access, was associated to an 
almost two-fold increase in operator radiation exposure at the thorax level. Our results confirm 
previous observations (13) that DAP is a weak predictor of operator exposure. 
In a recent meta-analysis, the difference in patient radiation exposure with radial as 
compared to femoral access was shown to narrow over time, suggesting that this difference may 
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not be present in current practice with experienced radial operators (5). Our findings support the 
notion that this difference persists in contemporary practice with experienced operators and it 
may be much greater than previously anticipated especially for complex multivessel intervention, 
such in non-ST segment elevation MI patients or those with diabetes mellitus. 
There are multiple potential explanations for the higher patient and operator radiation 
exposure associated with radial access. Procedures undertaken via radial access are technically 
more demanding for operators, especially in case of tortuosity of the subclavian-aortic axis, 
which can be observed in up to 30% of patients. More intense catheter manipulation is therefore 
required to overcome the vascular tortuosity and engage the coronary ostia; while the success 
rate in expert hands is similar to femoral access these maneuvers increase the fluoroscopy time 
and consequently the radiation dose to patients and operators. Our study confirms previous 
findings that fluoroscopy time and DAP are correlated and that both are significantly higher in 
the radial group (5,6). 
Other aspects should be considered regarding operator radiation exposure between radial 
and femoral access. Operator position with respect to X-ray tube and patient can affect radiation 
exposure by a factor of 40 during percutaneous procedures (14). At variance with operators’ 
position during femoral access, which is well standardized, operators’ position during radial 
access can substantially vary across centers or even within operators of the same center. In many 
instances, in order to better manipulate the catheter at insertion site in the radial artery, operators 
are closer to the X-ray tube and are less shielded by the leaded glass mobile panel. Also, the 
upper ceiling leaded glass is frequently positioned closer to the patient during radial instead of 
femoral access, in order to have direct access to the arterial sheath. Unfortunately, this translates 
into a less effective shielding capability from scatter radiation to the operator. 
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We did not observe a clear difference in terms of operator radiation dose between right 
and left radial. Several studies have compared operator radiation dose between radial left or right 
with inconsistent results (15-19); some showed less operator radiation dose with left instead of 
right radial but others reported similar radiation dose or higher operator dose with left radial. 
Various operator positions with respect to X-ray tube and inconsistent locations of mobile 
shielding devices across operators during right or left radial access may account for such 
heterogeneous observations. 
The absolute increase in DAP values for patients receiving radial instead of femoral 
access was 5.6 Gy*cm
2
. This difference is small and when expressed in terms of patient effective
dose is around 1.12mSv. Considering an additional lifetime cancer risk of 2.5%/Sv (1:40000) 
between age 40 and 60 years (20), radial access would be associated with an increased lifetime 
cancer risk of 1:35714 (0.0028%). One could consider this an acceptable risk considering that 
radial instead of femoral access may avoid 6 deaths for every 1000 patients treated (1). 
At variance from patients, interventional cardiologists perform thousands of procedures 
during their lifetime, with the potential for a cumulative effect. Operator exposure was almost 
twice higher with radial than femoral. Most of the operator body is covered with dedicated 
shields, such as lead apron and thyroid collar but some operator body regions, such as the head 
or arms, remain unprotected and directly exposed to radiation. Since a direct correlation between 
the dose and the risk of cancer even for very low dose of radiation exposure has been suggested 
(11) and taking also the deterministic risk of radiation into account (i.e. the cumulative risk of
cataract) (21) our findings should raise caution within the medical community; the incremental 
operator effective dose for a single procedure undertaken with radial instead of femoral access is 
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in the range of 1.1 µSv, corresponding to an additive 330 µSv every 300 procedures. This is 
similar to an additive radiation exposure of 17 chest X rays. 
Some studies suggested significant reductions in operator radiation doses using 
adjunctive protective drapes placed on patients (22-24) during radial access. Adjunctive personal 
protections as non-lead protective caps that reduce the head radiation doses should be also 
considered (25). 
Some limitations of our study should be considered. The use of thermoluminescent 
dosimeters allows only a cumulative analysis of the operator radiation dose. Hence, further 
analyses of the radiation dose in regards to the complexity of each single procedure performed 
was not possible, e.g. to target improvements in procedures to reduce radiation exposure. The use 
of electronic dosimeters that show radiation dose at the end of each procedure would have 
allowed a better understanding, which factors might ameliorate, or even negate, the differences 
in radiation exposure observed between radial and femoral access. However, thermoluminescent 
dosimeters allowed operators to remain blinded to study results. As per study protocol, we did 
not standardize patient preparation and set-up for radial access but asked each operator to follow 
his or her routine practice. The inclusion of 18 experienced operators from different centers 
likely provided a representative sample of current practice with radial access, but cannot be 
translated to less experienced operators or operators with limited training in the radial access site. 
The consistency of higher operator radiation exposure across participating operators with radial 
instead of femoral access suggests that the greater radiation dose is a common issue in current 
practice. The null finding of right versus left right radial comparison in terms of operator 
exposure may reflect a power issue and requires further investigation.  
Conclusions 
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In conclusion, our study shows that radial access is associated with higher operator and 
patient radiation exposure compared to femoral access. Radial operators and institutions should 
be sensitized towards radiation risks and adopt adjunctive radio-protective measures.  
Published in final edited form as: J Am Coll Cardiol. 2017 May 23;69(20):2530-2537. doi: 10.1016/j.jacc.2017.03.018
15 
PERSPECTIVES 
Competency in Medical Knowledge: Radial access as compared to femoral access reduces 
bleeding and mortality in patients with acute coronary syndrome undergoing invasive 
management. 
Competency in Patient Care: It remains unclear whether radial access increases the risk of 
operator or patient radiation exposure in contemporary practice when performed by expert 
operators. 
Translational Outlook 1:In this clinical trial that included 8404 patients and 18 radial expert 
operators equipped with dedicated dosimeters, performing 777 procedures and 767 patients, 
radial, as compared with femoral access is associated with greater operator and patient radiation 
exposure. 
Translational Outlook 2:Radial operators and institutions should be sensitized towards 
radiation risks and adopt adjunctive radio-protective measures. 
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Figure Legends 
Central Illustration: Operator radiation exposure for radial and femoral access. Red boxes: 
patients randomized to the femoral group. Grey boxes: patients randomized to the radial group. 
Figure 1: Operator radiation exposure for left and right radial access. Dark grey boxes: 
patients randomized to the radial right group. Light grey boxes: patients randomized to the radial 
left group.
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Table 1. Procedural characteristics of the full MATRIX population and the RAD-MATRIX subsample 
 MATRIX  RAD-MATRIX  
 Radial Femoral P Radial Femoral P 
 
Operators 
 
141 
 
155 
  
18 
 
18 
 
Patients 3448 3454  373 393  
Procedures 3773 3797  379 398  
PCI attempted 3073 (81%) 3094 (82%) 0.971 320 (84%) 324 (81%) 0.284 
Number of diagnostic 
catheters 
1.0 ± 0.6 1.0 ± 0.6 0.04 1.0 ± 0.6 1.0 ± 0.6 0.664 
Number of guiding catheters 1.6 ± 0.8 1.6 ± 0.7 <0.0001 1.5 ± 0.6 1.6 ± 0.6 0.034 
Cross over 273 (7%) 197 (5%) 0.0002 11 (3%) 14 (4%) 0.764 
Contrast dose (ml) 163 ± 82 164 ± 86 0.833 170 ± 86 162 ± 81 0.471 
Fluoroscopy time (min) 10.2 (6-16) 9.1 (5.1-15) <0.0001 10 (6-16) 8 (5-14) 0.0004 
DAP (Gy*cm
2
) 64.7 (28.6-120.3) 59.1 (25.9-109.5) 0.0001 74.1 (33.7-130) 67.5 (24.5-114.6) 0.751 
Patient Effective dose (mSv) 12.9 (5.7-24.1) 11.8 (5.2-21.9) <0.0001 14.8 (6.7-26) 13.5 (4.9-22.9) 0.238 
PCI Completed 3072 (81%) 3093 (82%) 0.971 320 (84%) 324 (81%) 0.284 
Treated artery       
   Left main 149 (5%) 122 (4%) 0.082 17 (5%) 21 (7%) 0.878 
   LAD 1541 (50%) 1534 (50%) 0.656 161 (50%) 154 (48%) 0.463 
   Left circumflex 876 (29%) 861 (28%) 0.554 87 (27%) 87 (27%) 0.908 
   Right coronary 1029 (34%) 1029 (33%) 0.850 110 (34%) 112 (35%) 0.868 
Number of stents 1.5 ± 0.9 1.5 ± 0.9 0.070 1.6 ± 0.9 1.4± 0.9 0.030 
Total stent length (mm) 68 ± 44 67 ± 43 0.276 75 ± 46 68 ± 43 0.131 
Thromboaspiration 798 (26%) 827 (27%) 0.498 96 (30%) 88 (27%) 0.681 
Results expressed as means± standard deviation, median with interquartile range, or absolute number with percentage in brackets. 
652 patients underwent two procedures and eight patients underwent three procedures during index hospitalization 
The p-values are estimated accounting for clusters at patient level in the MATRIX population and for clusters both at patient and operator level in the RAD-MATRIX 
subsample. 
DAP, dose area product; LAD, left anterior descending; PCI, percutaneous coronary intervention 
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Table 2. Operator radiation exposure for radial and femoral access 
 
 
 
Radial  
access 
 
Femoral  
access 
 
Difference between expected and actual 
sum of ranks for femoral access 
 
P 
 
Operators 
 
18 
 
18 
 
 
 
 
Procedures 379 398   
Median number of procedures 19.5 (9-23) 16 (10-36) 6 0.849 
Thorax dose per procedure (µSv) 77.3 (39.9-112) 40.6 (23.4-58.5) 74 0.019 
Wrist dose per procedure (µSv) 117 (68.3-197.8) 74.6 (44.2-115.3) 48.5 0.125 
Eye dose per procedure (µSv) 33.9 (14.2-44.8) 20.6 (9.6-32.7) 46 0.146 
Operator Effective dose (µSv) 2.3 (1.2-3.4) 1.2 (0.7-1.8) 74 0.019 
Dose normalized by FT(µSv/min)     
   Thorax dose 5.6 (4-9.8) 3.6 (3-4.9) 69 0.029 
   Wrist dose 8.8 (6.6-13.7) 5.3 (4.6-9.3) 41 0.195 
   Eye dose 2.4 (1.5-3.4) 1.7 (1-2.2) 37 0.242 
Dose normalized by DAP (µSv/Gy*cm²)     
   Thorax dose 0.8 (0.6-1.1) 0.5 (0.3-0.6) 77 0.015 
   Wrist dose 1.2 (0.9-2.3) 0.9 (0.6-1.3) 48 0.129 
   Eye dose 0.3 (0.2-0.5) 0.3 (0.1-0.4) 39 0.217 
Results expressed as median with interquartile range 
The p-values refer to superiority and come from two-sided unpaired Wilcoxon rank-sum test. 
DAP, dose area product; FT, fluoroscopy time  
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Table 3. Operator radiation exposure for left and right radial access 
 
 
Left radial 
access 
Right radial 
access 
Difference between expected and actual 
sum of ranks for right radial access 
P 
 
Operators 
 
14 
 
14 
 
 
 
 
Procedures 131 121   
Median number of procedures 6.5 (4-10) 9 (2-14) -14 0.519 
Thorax dose per procedure (µSv) 51.7 (33.2-91.9) 84.2 (47.1-146.1) -31 0.154 
Wrist dose per procedure (µSv) 86.5 (52.6-139.8) 152.6 (89.4-214.6) -35 0.108 
Eye dose per procedure (µSv) 14.8 (11-34.8) 38.6 (21.1-50) -38.5 0.077 
Operator Effective Dose (µSv) 1.6 (1-2.8) 2.6 (1.4-4.4) -31.0 0.016 
Dose normalized by FT (µSv/minute)    
   Thorax dose 4.1 (2.5-7.3) 7.1 (4-10.8) -36.5 0.093 
   Wrist dose 8.8 (4.6-11) 11.5 (6.4-15.4) -30 0.168 
   Eye dose 1.3 (0.6-2.9) 2.6 (1.3-3.9) -32 0.141 
Dose normalized by DAP (µSv/Gy*cm²)     
   Thorax dose 0.6 (0.4-0.8) 0.7 (0.5-1.1) -27 0.215 
   Wrist dose 1.0 (0.6-1.2) 1.2 (0.9-2.3) -25.5 0.241 
   Eye dose 0.2 (0.1-0.5) 0.3 (0.2-0.5) -17 0.435 
Results expressed as median with interquartile range  
The p-values come from two-sided unpaired Wilcoxon rank-sum test. 
DAP, dose area product; FT, fluoroscopy time 
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